Comparison of subconjunctivally injected bevacizumab, ranibizumab, and pegaptanib for inhibition of corneal neovascularization in a rat model

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 136-140

  Akar, Ebru Eren ^a   Öner, Veysi ^b   Küçükerdönmez, Cem ^c   Akova, Yonca Aydin ^d  

^a Artvin State Hospital   (Turkey)

^b RECEP TAYYIP ERDOGAN UNIVERSITY   (Turkey)

^c IZMIR UNIVERSITY   (Turkey)

^d BAYINDIR HOSPITAL   (Turkey)

Author keywords

Bevacizumab; Corneal neovascularization; Pegaptanib; Ranibizumab; Subconjunctival injection

Indexed keywords

EID: 84887394657     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.02.05     Document Type: Article

References (24)

1. Chang JH, Gabison EE, Kato T, Azar DT. Corneal neovascularization. Curr Opin Ophthalmol. 2001; 12(4): 242-249.
2. Lee P, Wang CC, Adamis AP. Ocular neovascularization: an epidemiologic review. Surv Ophthalmol. 1998; 43(3): 245-269.
3. Dana MR, Streilein JW. Loss and restoration of immune privilege in eyes with corneal neovascularization. Invest Ophthalmol Vis Sci. 1996; 37(12): 2485-494.
4. Kenyon BM, Voest EE, Chen C.C., Flynn E., Folkman J, D'Amato RJ. A model of angiogenesis in the mouse cornea. Invest Ophthalmol Vis Sci. 1996; 37(8): 1625-1632.
5. Phillips GD, Stone AM, Jones B.D., chultz JC, Whitehead RA, Knighton DR. Vascular endothelial growth factor (rhVEGF165) stimulates direct angiogenesis in the rabbit cornea. In Vivo. 1994; 8(6): 961-965.
6. Amano S, Rohan R, Kuroki M., Tolentino M, Adamis AP. Requirement for vascular endothelial growth factor in wound-and inflammation-related corneal neovascularization. Invest Ophthalmol Vis Sci. 1998; 39(1): 18-22.
7. Hashemian MN, Z-Mehrjardi H, Moghimi S, Tahvildari M., Mojazi-Amiri H. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. Ophthalmic Res. 2011; 46(1): 50-54.
8. Pérez-Santonja J.J., Campos-Mollo E, Lledó-Riquelme M, Javaloy J, Alió JL. Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and sunitinib (Anti-VEGF and Anti-PDGF) in an animal model. Am J Ophthalmol. 2010; 150(4): 519-528.
9. Habot-Wilner Z., Barequet IS, Ivanir Y, Moisseiev J., Rosner M. The inhibitory effect of different concentrations of topical bevacizumab on corneal neovascularization. Acta Ophthalmol. 2010; 88(8): 862-867.
10. You IC, Kang IS, Lee S.H., Yoon KC. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization. Acta Ophthalmol. 2009; 87(6): 653-658.
11. Oner V, Küçükerdönmez C, Akova YA, Çolak A, Karalezli A. Topical and Subconjunctival Bevacizumab for Corneal Neovascularization in an Experimental Rat Model. Ophthalmic Res. 2012; 48(3): 118-123.
12. Sener E, Yuksel N, Yildiz D.K., Yilmaz B., Ozdemir O, Caglar Y, Degirmenci E. The impact of subconjuctivally injected EGF and VEGF inhibitors on experimental corneal neovascularization in rat model. Curr Eye Res. 2011; 36(11): 1005-1013.
13. Dursun A, Arici MK, Dursun F, Ozec A.V., Toker MI, Erdogan H, Topalkara A. Comparison of the effects of bevacizumab and ranibizumab injection on corneal angiogenesis in an alkali burn induced model. Int J Ophthalmol. 2012; 5(4): 448-451.
14. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985; 4(5): 531-535.
15. Manzano RP, Peyman GA, Khan P, Carvounis P.E., Kivilcim M., Ren M, Lake JC, Chévez-Barrios P. Inhibition of experimental corneal neovascularisation by bevacizumab (Avastin) Br J Ophthalmol. 2007; 91(6): 804-807.
16. Gupta D, Illingworth C. Treatments for corneal neovascularization: a review. Cornea. 2011; 30(8): 927-938.
17. Erdurmus M, Yagci R, Yilmaz B., Hepsen IF, Turkmen C, Aydin B, Karadag R. Inhibitory effects of topical thymoquinone on corneal neovascularization. Cornea. 2007; 26(6): 715-719.
18. Neufeld G, Cohen T, Gengrinovitch S., Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999; 13(1): 9-22.
19. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer. 2002; 2(10): 727-739.
20. Bhisitkul RB. Vascular endothelial growth factor biology: clinical implications for ocular treatments. Br J Ophthalmol. 2006; 90(12): 1542-1547.
21. Bock F, Onderka J, Dietrich T., Bachmann B, Kruse FE, Paschke M, Zahn G., Cursiefen C. Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangiogenesis. Invest Ophthalmol Vis Sci. 2007; 48(6): 2545-2552.
22. Campa C, Harding SP. Anti-VEGF compounds in the treatment of neovascular age related macular degeneration. Curr Drug Targets. 2011; 12(2): 173-181.
23. Lu F, Adelman RA. Are intravitreal bevacizumab and ranibizumab effective in a rat model of choroidal neovascularization? Graefes Arch Clin Exp Ophthalmol. 2009; 247(2): 171-177.
24. Riazi-Esfahani M., Peyman GA, Aydin E, Kazi A.A., Kivilcim M., Sanders DR. Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. Cornea. 2006; 25(7): 801-805.